Compare ASIC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | XNCR |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | 203 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.6M | 881.9M |
| IPO Year | N/A | 2013 |
| Metric | ASIC | XNCR |
|---|---|---|
| Price | $19.27 | $11.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $26.75 | $22.33 |
| AVG Volume (30 Days) | 62.6K | ★ 691.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $34.21 | N/A |
| Revenue Next Year | $34.65 | $4.80 |
| P/E Ratio | $98.60 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $16.35 | $6.92 |
| 52 Week High | $23.88 | $18.69 |
| Indicator | ASIC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 44.32 |
| Support Level | $18.73 | $11.02 |
| Resistance Level | $21.21 | $13.28 |
| Average True Range (ATR) | 1.01 | 0.81 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 14.93 | 20.00 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.